• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » INC Research gains iCardiac Site Certification

INC Research gains iCardiac Site Certification

October 2, 2015
CenterWatch Staff

INC Research Holdings, a global phase I to IV CRO, has been certified to use the iCardiac Early Precision QT approach for evaluating the cardiac safety of new compounds in phase I clinical development. INC’s use of iCardiac Early Precision QT may help customers reduce costs, and increase the accuracy, reliability and speed of cardiac safety testing in clinical research.

“INC Research continually seeks innovations that enhance the full drug development lifecycle,” said CEO Jamie Macdonald. “Achieving certification to conduct trials using iCardiac Early Precision QT is a prime example of the company’s focus on driving efficiency for customers through new approaches. As drug development becomes increasingly complex and the amount of data captured, stored and applied multiplies exponentially, this approach has the potential for significant time and cost savings for customers.”

Since 2005, the FDA has required all new compounds under development to be tested to determine their impact on the QT interval—the time between the start of the Q wave and the end of the T wave during the heart’s electrical cycle. A lengthened QT interval indicates potential safety risk factors for a new drug.

With the technology in place, INC may be able to eliminate the need for a separate, dedicated Thorough QT (TQT) study, which can cost between $2 million and $5 million. By applying the approach, INC can help companies spend only a fraction of that amount and collect cardiac safety data during phase I trials rather than during later stage trials. By making cardiac safety assessments earlier in clinical development, researchers may be able to speed the development process, help to avoid promising drugs being inappropriately eliminated through inaccurate cardiac data, bring new therapies to market sooner, better allocate resources and reduce spending.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing